Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer
- PMID: 11331332
- DOI: 10.1200/JCO.2001.19.9.2527
Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer
Abstract
Purpose: To determine the efficacy and toxicity of the drug combination of carboplatin, paclitaxel, and gemcitabine in patients with advanced urothelial carcinoma.
Patients and methods: Patients eligible included those with advanced urothelial malignancy of any histology, no previous chemotherapy for metastatic disease, Southwest Oncology Group performance status of 2 or less, serum creatinine levels of 2 mg/dL or less, and adequate bone marrow and hepatic function. Treatment consisted of paclitaxel 200 mg/m2, carboplatin (target area under the curve = 5) on day 1, and gemcitabine 800 mg/m2 on days 1 and 8, repeated every 21 days.
Results: Forty-nine patients (44 men and five women) were enrolled; the patients' median age was 63 years, and their median creatinine clearance was 78 mL/min (range, 26 to 165 mL/min). Forty-three patients had transitional cell carcinoma, and six had squamous cell carcinoma or mixed histology. Ten patients had metastases to lymph nodes only, six had locally advanced disease, four had locally recurrent disease, 24 patients had visceral metastases, and five had soft tissue metastases. Twenty-one patients had disease in one site, 16 in two sites, and 12 in three sites. A total of 272 cycles were administered (median, six cycles; range, 1 to 15 cycles). Major toxicities were grade 3 and 4 neutropenia in 17 and 19 patients, respectively; grade 3 and 4 thrombocytopenia in 15 and six patients, respectively; grade 3 and 4 anemia in 10 and two patients, respectively; grade 3 neuropathy in four patients; and diarrhea in two patients. The incidence of febrile neutropenia was 1.4%; no patients died of drug toxicity. Forty-seven of the 49 patients were assessable for response. Fifteen (32%) patients experienced a complete response, and 17 (36%) patients experienced a partial response (32 of 47 patients, 68%; 95% confidence interval, 56.27 to 82.86). Responses were seen in all sites, including 15 (68%) of 22 patients with visceral metastases. The median survival was 14.7 months, with a 1-year survival of 59%.
Conclusion: Combination paclitaxel, carboplatin, and gemcitabine is active; an encouraging number of patients with advanced urothelial carcinoma treated with this regimen experienced complete remission.
Similar articles
-
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.Cancer. 2005 Jun 1;103(11):2298-303. doi: 10.1002/cncr.21078. Cancer. 2005. PMID: 15856431 Clinical Trial.
-
Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.Invest New Drugs. 2014 Feb;32(1):188-94. doi: 10.1007/s10637-013-0054-5. Epub 2013 Dec 10. Invest New Drugs. 2014. PMID: 24318901 Free PMC article. Clinical Trial.
-
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.J Clin Oncol. 2007 Jun 1;25(16):2218-24. doi: 10.1200/JCO.2006.08.0994. J Clin Oncol. 2007. PMID: 17538166 Clinical Trial.
-
[Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].Gan To Kagaku Ryoho. 2011 Mar;38(3):481-4. Gan To Kagaku Ryoho. 2011. PMID: 21403460 Review. Japanese.
-
Current and future perspectives in advanced bladder cancer: is there a new standard?Semin Oncol. 2002 Feb;29(1 Suppl 3):3-14. doi: 10.1053/sonc.2002.30750. Semin Oncol. 2002. PMID: 11894002 Review.
Cited by
-
A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium.BMC Cancer. 2007 Jun 9;7:98. doi: 10.1186/1471-2407-7-98. BMC Cancer. 2007. PMID: 17559681 Free PMC article. Clinical Trial.
-
State-of-the-art management of metastatic disease at initial presentation or recurrence.World J Urol. 2006 Nov;24(5):543-56. doi: 10.1007/s00345-006-0115-x. World J Urol. 2006. PMID: 17031652 Review.
-
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG).Target Oncol. 2019 Feb;14(1):15-32. doi: 10.1007/s11523-019-00619-7. Target Oncol. 2019. PMID: 30694442 Review.
-
Novel strategies for treating relapsed/refractory urothelial carcinoma.Expert Rev Anticancer Ther. 2010 Dec;10(12):1917-32. doi: 10.1586/era.10.182. Expert Rev Anticancer Ther. 2010. PMID: 21110758 Free PMC article. Review.
-
Chemotherapy in advanced bladder cancer: current status and future.J Hematol Oncol. 2011 Sep 9;4:35. doi: 10.1186/1756-8722-4-35. J Hematol Oncol. 2011. PMID: 21906310 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical